Metropolis Healthcare Limited (NSE:METROPOLIS)

India flag India · Delayed Price · Currency is INR
1,756.30
-8.60 (-0.49%)
Apr 25, 2025, 2:30 PM IST
-4.03%
Market Cap 90.48B
Revenue (ttm) 13.17B
Net Income (ttm) 1.52B
Shares Out 51.27M
EPS (ttm) 29.57
PE Ratio 59.68
Forward PE 44.21
Dividend 4.00 (0.23%)
Ex-Dividend Date n/a
Volume 76,639
Average Volume 97,521
Open 1,765.20
Previous Close 1,764.90
Day's Range 1,726.00 - 1,788.00
52-Week Range 1,315.00 - 2,318.30
Beta 0.12
RSI 67.45
Earnings Date May 21, 2025

About Metropolis Healthcare

Metropolis Healthcare Limited provides diagnostic services in India and internationally. The company offers clinical laboratory testing, and profiles services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, and confirmation and/or monitoring of the disease. In addition, the company offers corporate wellness, laborat... [Read more]

Sector Healthcare
Founded 1981
Employees 4,313
Stock Exchange National Stock Exchange of India
Ticker Symbol METROPOLIS
Full Company Profile

Financial Performance

In 2023, Metropolis Healthcare's revenue was 12.08 billion, an increase of 5.18% compared to the previous year's 11.48 billion. Earnings were 1.28 billion, a decrease of -10.54%.

Financial Statements

News

Metropolis Healthcare to acquire Dr. Ahujas’ Pathology & Imaging Centre for Rs 35 crore

Metropolis Healthcare Limited, India’s second-largest pathology laboratory chain, has announced a strategic acquisition to bolster its foothold in North India. The company’s wholly owned subsidiary, M...

18 days ago - Business Upturn

Metropolis Healthcare posts 10% YoY revenue growth in Q4 FY25, wellness segment drives performance

Metropolis Healthcare Limited reported a 10% year-on-year revenue growth for the fourth quarter of FY25, despite facing challenges in the acute testing and specialty segments. The company, which opera...

20 days ago - Business Upturn

Stocks hitting 52-week low today, April 1: Titan Company, Tata Elxsi, UCO Bank, Birlasoft, Metropolis Healthcare and more

The Indian stock market experienced a significant downturn on April 1, as both major indices, Sensex and Nifty, closed in the red for the second consecutive session. The Sensex plunged by 1,390.41 poi...

23 days ago - Business Upturn

Metropolis Healthcare to acquire scientific pathology’s business in Agra for up to Rs 83 Crore

Metropolis Healthcare Limited has announced the acquisition of the business operations of Dr. Ashok Kumar Sharma’s Scientific Pathology, a diagnostic service provider in Agra and neighboring towns. Th...

7 weeks ago - Business Upturn

Metropolis Health shares jump 3% as revenue rises 11% YoY in Q3

Metropolis Health shares jumped more than 3% in morning trade after the company announced its solid Q3 results. As of 10:09 AM, the shares were trading 2.85% higher at Rs 1,787.45. The company posted ...

2 months ago - Business Upturn

Metropolis Healthcare Q3 FY25 results: Revenue Up 9.2% YoY to Rs 29,991.31 lakhs, net profit soars 2.6% YoY

In December 2024, the company announced the acquisition of Core Diagnostics Private Limited, a leading diagnostic service provider in India, for ₹24,683 lakhs. This acquisition is expected to enhance ...

2 months ago - Business Upturn

Metropolis Healthcare Ltd (BOM:542650) Q3 2025 Earnings Report Preview: What To Look For

Metropolis Healthcare Ltd (BOM:542650) Q3 2025 Earnings Report Preview: What To Look For

2 months ago - GuruFocus

Metropolis Healthcare acquires 100% stake in Core Diagnostics for Rs 246.83 crores

The total cost of the acquisition is INR 246.83 crores, with Core Diagnostics now becoming a wholly owned subsidiary of Metropolis Healthcare. The transaction is expected to be completed within 60 day...

4 months ago - Business Upturn

Goldman Sachs maintains ‘Sell’ rating on Metropolis, raises target price to Rs 1,775, expecting 17% downside

Goldman Sachs has reiterated its ‘Sell’ rating on Metropolis Healthcare, increasing the target price to ₹1,775 from ₹1,725, which suggests a potential 17% downside from the current market price (CMP) ...

5 months ago - Business Upturn

Metropolis Healthcare Ltd (BOM:542650) Q1 2025 Earnings Call Transcript Highlights: Strong ...

Metropolis Healthcare Ltd (BOM:542650) Q1 2025 Earnings Call Transcript Highlights: Strong Financial Performance and Strategic Expansion

9 months ago - GuruFocus

Q1 2025 Metropolis Healthcare Ltd Earnings Call Transcript

Q1 2025 Metropolis Healthcare Ltd Earnings Call Transcript

9 months ago - GuruFocus